bullish
Aurobindo Pharma Ltd - Slight Dip in Profitability Due to Temporary Activities
Quarterly revenue reached Rs. 7,796 crore, reflecting an 8% y-o-y and 3% q-o-q increase, exceeding our estimates by 1%, while PAT was Rs. 817 crore
What is covered in the Full Insight:
- Executive Summary
- Financial Performance
- Market Expansion and Product Approvals
- Management Commentary and Future Outlook
- Valuation and Recommendation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Discussions
(Paid Plans Only)
x